MEDIA CENTER - 2017

December 1, 2017
APIM Therapeutics has announced that the company has closed a
Financing round raising 25 mNOK (3 m$). Funds will be used to file a Clinical Trial Application
(CTA) and start the clinical development program of APIM Therapeutics’ anti-cancer lead
compound, ATX-101. A copy of the press release is available
here.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see www.ntnu.no.

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit www.sarsiaseed.com to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit www.televenture.no to find out more.